← BLACKLEDGER Content Feed

Buying • NEUROPHAGE x BLACKLEDGER • 8 min read • 2026-06-17

BLACKLEDGER Buying Watch: RENDER, ABNB, TIA

BLACKLEDGERMarket ResearchBuyingRENDERABNBTIAAFRM
BLACKLEDGER Buying public market research update for RENDER, ABNB, TIA

BLACKLEDGER's latest buying watch update tracks RENDER, ABNB, TIA, AFRM, CRSP, NTLA from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.

Buying Watch Data

The dedicated feed category for this update is Buying. The latest public scan timestamp is 2026-06-17T08:00:48.027718+00:00.

Educational Context: How To Use This Page

This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.

RENDER Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Render USD. Market class: crypto. Public bias: Bull. Public tier: Extended.

Render (RENDER) is a cryptocurrency launched in 2019and operates on the Ethereum platform. Render has a current supply of 533,503,434.29407415 with 518,743,261.01407415 in circulation. The last known price of Render is 1.75266195 USD and is down -2.10 over the last 24 hours. It is currently trading on 653 active market(s) with $38,966,579.47 traded over the last 24 hours. More information can be found at https://rendernetwork.com/.

Why RENDER Is In This Public Update

Outside Public Headlines / Source Notes

ABNB Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Airbnb, Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.

Airbnb, Inc., together with its subsidiaries, operates a platform for stays, experiences, and services worldwide. The company's marketplace connects hosts and guests online or through mobile devices to book spaces, experiences, and services. It also offers gift cards. The company was formerly known as AirBed & Breakfast, Inc. and changed its name to Airbnb, Inc. in November 2010. Airbnb, Inc. was founded in 2007 and is headquartered in San Francisco, California.

Why ABNB Is In This Public Update

Outside Public Headlines / Source Notes

TIA Public Research Bio

Name: Celestia USD. Market class: crypto. Public bias: Bull. Public tier: A-List.

Celestia (TIA) is a cryptocurrency launched in 2023and operates on the Osmosis platform. Celestia has a current supply of 1,168,685,161.483695 with 919,932,996.62251 in circulation. The last known price of Celestia is 0.41032494 USD and is up 9.40 over the last 24 hours. It is currently trading on 356 active market(s) with $62,374,277.59 traded over the last 24 hours. More information can be found at https://www.celestia.org.

Why TIA Is In This Public Update

Outside Public Headlines / Source Notes

AFRM Public Research Bio

Name: Affirm Holdings, Inc.. Market class: stock. Public bias: Bull. Public tier: A-List.

Affirm Holdings, Inc. operates payment network in the United States, Canada, and internationally. Its platform includes point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company's commerce platform, agreements with originating banks, and capital markets partners enables consumers to pay for a purchase over time. It has active merchants covering [redacted]ll businesses, large enterprises, direct-to-consumer brands, brick-and-mortar stores, and companies with an omni-channel presence. The company's merchants represent a range of industries, including sporting goods and outdoors, home and lifestyle, travel and ticketing, electronics, fashion and beauty, equipment and auto, and general merchandise. Affirm Holdings, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Why AFRM Is In This Public Update

Outside Public Headlines / Source Notes

CRSP Public Research Bio

Name: CRISPR Therapeutics AG. Market class: stock. Public bias: Bull. Public tier: A-List.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemog

Why CRSP Is In This Public Update

Outside Public Headlines / Source Notes

NTLA Public Research Bio

Name: Intellia Therapeutics, Inc.. Market class: stock. Public bias: Bull. Public tier: A-List.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioed[redacted]. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeu

Why NTLA Is In This Public Update

Outside Public Headlines / Source Notes

What The Public Data Shows

The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.

Why This Category Matters

The Buying section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.

Research-Only Notice

BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.

Research-only. No execution signal. Not financial advice.